Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma

Abstract EN

Objective.

The aim of this study is to evaluate the association of genetic polymorphisms in Cytochrome P450 2D6(CYP2D6) and the change in VEGF levels with the response to propranolol in patients with Infantile hemangiomas (IH).

Methods.

IH patients who underwent over six months of propranolol therapy and received oral propranolol only were enrolled.

The target dose of propranolol was 1 mg kg−1day−1.

Deoxyribonucleic acid was obtained from venous blood leukocytes.

Genotypes of CYP2D6 (rs1065852 and rs1135840) were tested by polymerase chain reaction (PCR) and by sequencing the products.

Baseline serum VEGF and serum VEGF one month after treatment were measured.

The clinical responses after six months of treatment were evaluated.

Genotypes of CYP2D6 (rs1065852 and rs1135840) and VEGF levels were compared between good responders and poor-to-moderate responders.

Results.

72 patients were enrolled in the study.

Patients with CYP2D6 (rs1135840) G/G homozygote had the highest response rate to propranolol.

No significant association was found between the response rates and CYP2D6 (rs1065852) polymorphism.

No significant differences were found in baseline serum VEGF, serum VEGF one month after treatment, and VEGF ratio between good responders and poor-to-moderate responders.

Conclusion.

The response to propranolol treatment in IH patients was associated with the gene polymorphism of CYP2D6 (rs1135840).

A low-dose propranolol regimen was effective and safe in young infants with IH.

The change of serum VEGF levels after one month’s treatment could not be used to predict the response rate to propranolol.